The April 2023 catch-up price reductions are causing significant concern across the biopharmaceutical sector and while the framework has captured many recently reimbursed brands it has the appearance of targeting one particular group of medicines. …
The appearance of a pricing policy targeting one group of medicines
August 19, 2022 Latest NewsBioPharma
Latest Video
Georgia Forrest
New Stories
-
A 'fit for purpose' HTA system will be accompanied by a 'fit for purpose' cost recovery framework
December 19, 2025 - - Latest News -
Cleo Diagnostics raises funds to accelerate US launch and advance ovarian cancer screening
December 18, 2025 - - Australian Biotech -
Actinogen crosses key milestone as pivotal Alzheimer’s trial fully enrols
December 18, 2025 - - Australian Biotech -
Pharmac scraps plan to remove low-ranked medicines from options for funding list
December 18, 2025 - - Latest News -
PBAC reflects on a year shaped by major reviews and rising workload
December 18, 2025 - - Latest News -
Priceline moves to stabilise banner group as pressures force administrators
December 17, 2025 - - Latest News -
Rare Cancers Australia gearing up for 2026 Kosi Challenge with Pharma Cup up for grabs again
December 17, 2025 - - Latest News